CIM
PTGX icon

Cambria Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Cambria Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$965K Buy
7,869
+1,004
+15% +$105K 0.05% 332
2026
Q1 		$724K Sell
6,865
-95
-1% -$8.41K 0.04% 288
2025
Q4 		$608K Sell
6,960
-3,984
-36% -$326K 0.04% 366
2025
Q3 		$727K Buy
10,944
+2,187
+25% +$124K 0.04% 271
2025
Q2 		$484K Sell
8,757
-243
-3% -$11.7K 0.03% 297
2025
Q1 		$435K Sell
9,000
-1,575
-15% -$66K 0.03% 248
2024
Q4 		$408K Buy
+10,575
New +$461K 0.02% 273

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Cambria Investment Management's PTGX Position: Q2 2026 in Review

Cambria Investment Management increased its Protagonist Therapeutics (PTGX) stake by 15% in Q2 2026, buying an estimated $105K and bringing the position to 7,869 shares worth $965K. The position accounts for 0.05% of the portfolio, ranked #332.

Cambria Investment Management first reported a position in PTGX in Q4 2024 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Cambria Investment Management held 7,869 shares of Protagonist Therapeutics worth $965K as of Q2 2026.
  • Cambria Investment Management bought 1,004 Protagonist Therapeutics shares in Q2 2026, an estimated $105K.
  • Protagonist Therapeutics made up 0.05% of Cambria Investment Management's portfolio in Q2 2026, its #332 holding.
  • Cambria Investment Management first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.